Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Natalie Gukasyan Alan Kooi DavisFrederick S BarrettMary P CosimanoNathan D SepedaMatthew W JohnsonRoland R Griffiths

Published in: Journal of psychopharmacology (Oxford, England) (2022)

These findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients.

Keyphrases

major depressive disorder
bipolar disorder
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
liver failure
prognostic factors
peritoneal dialysis
respiratory failure
extracorporeal membrane oxygenation
aortic dissection